Oral calcimimetics on secondary hyperparathyroidism of uremia

Imanishi, Y.

Clinical Calcium 27(4): 561-566

2017


ISSN/ISBN: 0917-5857
PMID: 28336833
Document Number: 17203
Secondary hyperparathyroidism of uremia is associated with poor health outcomes, including all-cause mortality, cardiovascular mortality, and fractures. Standard therapy for secondary hyperparathyroidism includes vitamin D receptor activators, and phosphate binders. Persistently elevated parathyroid hormone(PTH)levels may require the addition of calcimimetics which sensitizes calcium-sensing receptors on the parathyroid glands.

Document emailed within 1 workday
Secure & encrypted payments

Oral calcimimetics on secondary hyperparathyroidism of uremia